BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXApr 24, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXMar 27, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXFeb 14, 2017, 12:02 PM UTC
BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXFeb 14, 2017, 12:02 PM UTC
BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXFeb 14, 2017, 12:02 PM UTC
BusinessAxsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXMar 17, 2016, 11:00 AM UTC
